Company Overview of Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis...
1901 North Roselle Road
Schaumburg, IL 60195
Founded in 2006
Key Executives for Sagent Pharmaceuticals, Inc.
President, Chief Legal Officer and Corporate Secretary
Total Annual Compensation: $328.9K
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $344.8K
Executive Vice President of National Accounts & Corporate Development
Total Annual Compensation: $297.1K
Compensation as of Fiscal Year 2014.
Sagent Pharmaceuticals, Inc. Key Developments
Sagent Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year 2015
May 5 15
Sagent Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s net revenue was $82.6 million, an increase of $11.8 million, or 17%, compared to $70.9 million in the first quarter of 2014. The increase was driven primarily by the $7.4 million from the addition of Omega on October 1, 2014. Net loss of $1.9 million or diluted loss per share of $0.06, inclusive of $3.1 million ($0.10 per share) of costs related to management transition, acquisition-related costs and the inventory step up on Omega, net of tax. Adjusted EBITDA was $9.0 million, a decline of $0.5 million, or 6% compared to $9.6 million in the first quarter of 2014. Loss from operations was $189,000 compared to income from operations of $6,632,000 a year ago. Loss before income taxes was $1,575,000 compared to income before income taxes of $6,333,000 a year ago. EBITDA was $1,803,000 compared to $8,358,000 a year ago.
For the year 2015, the company expected net revenue to be in the range of $325 to $375 million. The company anticipates adjusted EBITDA in the range of $20 to $50 million. The company expected EBITDA to be in the range of $11 million to $39 million. Expected net income to be in the range of $3 million loss to $13 million earnings. Adjusted gross profit will be in the range of 27% to 31%.
Sagent Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2015
Apr 29 15
Sagent Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2015., at 08:00 Central Standard Time. Location: The Stonegate Conference and Banquet Centre. Agenda: To elect as Class I and Class III directors the nominees named in the Proxy Statement; to ratify the retention of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; to an advisory vote to approve the compensation of the named executive officers; and to transact any other business properly presented at the meeting or any adjournment thereof.
Sagent Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 05, 2015
Apr 27 15
Sagent Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on May 05, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions